Subscribe
wk1003mike / Shutterstock.com
1 May 2025NewsAmericasMarisa Woutersen

US warns of rising counterfeit drug threat from India and China

Latest report highlights increasing concerns over counterfeit pharmaceuticals, IP barriers, and market access challenges | Key countries to watch include India, China, the UAE, and Singapore | Report also outlines challenges in Mexico, Russia, Brazil, and Indonesia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

More on this story

Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

More features

Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors